Close Menu

NEW YORK (GenomeWeb)  — Medicare contractor Palmetto GBA has issued a final local coverage determination (LCD) for Myriad Genetics' myPath Melanoma test, the firm announced today.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.